Table 1.
| TIM-3 | % of positive cells | VISTA | % of positive cells | |||||
|---|---|---|---|---|---|---|---|---|
| Positive cases | Number of cases | Positive cases | Number of cases | |||||
| n (%) | 5%–15% | 15%–50% | >50% | n (%) | 5%–15% | 15%–50% | >50% | |
| PTCL, NOS | 3/37 (8) | 1 | 3 | 0 | 2/37 (5) | 1 | 6 | 0 |
| ALCL | 0/11 (0) | 0 | 0 | 0 | 0/11 (0) | 0 | 0 | 0 |
| AITL | 0/6 (0) | 0 | 0 | 0 | 2/6 (33) | 0 | 2 | 0 |
| EATL | 1/3 (33) | 0 | 0 | 1 | 2/3 (66) | 0 | 0 | 2 |
| ENKTCL | 0/3 (0) | 0 | 0 | 0 | 0/3 (0) | 0 | 0 | 0 |
AITL, angioimmunoblastic T cell lymphoma; ALCL, anaplastic large cell lymphoma; EATL, enteropathy-associated T cell lymphoma; ENKTCL, extranodal natural killer T cell lymphoma ; PTCL, peripheral T cell lymphoma; TIM-3, T cell immunoglobulin-3; VISTA, V-domain Ig-containing suppressor of T cell activation.